ASCO 2021

REVIEW UroToday

Viewing 1-20 of 198 articles

ASCO 2021: Systemic Therapy Considerations After Immunotherapy Combination or Monotherapy in Advanced Renal Cell Carcinoma

ASCO 2021: Sequencing Therapies in Advanced Kidney Cancer in the Contemporary Era – Integration of Multimodality Treatment in Advanced Kidney Cancer: The Roles of Surgery and Radiation Therapy

ASCO 2021: Sequencing Therapies in Advanced Kidney Cancer in the Contemporary Era – Integration of Multimodality Treatment in Advanced Kidney Cancer: Novel Therapeutics on the Horizon in Advanced Kidney Cancer

ASCO 2021: The Variability in Prostate Cancer Treatments and Outcomes Based on Geographic Location and Race

ASCO 2021: Optimizing Urothelial Cancer Management From Organ-Confined to Metastatic Disease: A Multidisciplinary Approach – Urologic Oncologist Perspective

ASCO 2021: Optimizing Urothelial Cancer Management From Organ-Confined to Metastatic Disease: A Multidisciplinary Approach – Radiation Oncologist Perspective

ASCO 2021: Optimizing Urothelial Cancer Management From Organ-Confined to Metastatic Disease: A Multidisciplinary Approach – Medical Oncologist Perspective

ASCO 2021: Clinical Activity of Durvalumab and Savolitinib in Met-Driven, Metastatic Papillary Renal Cancer

ASCO 2021: Randomized Phase Ib Study To Evaluate Safety, Pharmacokinetics and Therapeutic Activity of Simlukafusp α in Combination With Atezolizumab ± Bevacizumab in Patients With Unresectable Advanced/ Metastatic Renal Cell Carcinoma (Rcc) (NCT03063762)

ASCO 2021: Making Strides in the Treatment of Non-Clear Cell Carcinoma: Are We Ready for Adaptive and Biomarker-Driven Strategies?

ASCO 2021: Pembrolizumab (Pembro) plus Axitinib (Axi) Versus Sunitinib as First-Line Therapy for Advanced Clear Cell Renal Cell Carcinoma (ccRCC): Results from 42-Month Follow-up of KEYNOTE-426

ASCO 2021: Complementary Detection of Genomic Alterations in Metastatic Castration Resistant Prostate Cancer From CheckMate 9KD Through Analyses of Tumor Tissue and Plasma DNA

ASCO 2021: Real-World Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Receiving Front-Line Axitinib plus Pembrolizumab Versus Ipilimumab plus Nivolumab

ASCO 2021: Vorolanib, Everolimus, and the Combination in Patients with Pretreated Metastatic Renal Cell Carcinoma (CONCEPT Study): A Randomized, Phase 3, Double-Blind, Multicenter Trial

ASCO 2021: An Open-Label, Pharmacokinetic Study to Determine the Bioavailability, Safety and Tolerability of Single Dose Oral Docetaxel in Metastatic Prostate Cancer Patients Treated with IV Docetaxel

ASCO 2021: Differences in Toxicity and Outcomes: A Race-based Case Study

ASCO 2021: CANTATA: Primary Analysis of a Global, Randomized, Placebo-Controlled, Double-Blind Trial of Telaglenastat (CB-839) + Cabozantinib Versus Placebo + Cabozantinib in Advanced/Metastatic Renal Cell Carcinoma Patients on Immune Checkpoint Inhibitor

ASCO 2021: Genomic Disparities Across Gleason Scores

ASCO 2021: Safety and Efficacy of AMG 160, a Half-Life Extended BiTE Immune Therapy Targeting PSMA, and Other Therapies for Metastatic Castration-Resistant Prostate Cancer

ASCO 2021: Expanding VEGF Blockade Combination Therapeutic Options in Advanced Renal Cell Carcinoma

1
2
3
4
5
6
7
8
9
10